Actively Recruiting
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Led by Haukeland University Hospital · Updated on 2024-10-29
60
Participants Needed
1
Research Sites
354 weeks
Total Duration
On this page
Sponsors
H
Haukeland University Hospital
Lead Sponsor
U
University of Bergen
Collaborating Sponsor
AI-Summary
What this Trial Is About
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
CONDITIONS
Official Title
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Included in OVERLORD-MS (NCT04578639)
- Willing to attend laboratory for blood sample collection at scheduled time points
You will not qualify if you...
- Not willing to attend laboratory for blood sample collection at scheduled time points
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Haukeland University Hospital, Deparment of medical biochemistry and pharmacology
Bergen, Vestland, Norway, 5021
Actively Recruiting
Research Team
T
Trond T. Serkland, M.D.
CONTACT
S
Silje Skrede, M.D., PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here